Načítá se...
Different infusion durations for preventing platinum‐induced hearing loss in children with cancer
BACKGROUND: Platinum‐based therapy, including cisplatin, carboplatin or oxaliplatin, or a combination of these, is used to treat a variety of paediatric malignancies. Unfortunately, one of the most important adverse effects is the occurrence of hearing loss or ototoxicity. In an effort to prevent th...
Uloženo v:
| Vydáno v: | Cochrane Database Syst Rev |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Ltd
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6516894/ https://ncbi.nlm.nih.gov/pubmed/29975402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010885.pub4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|